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Salicylate, the active component of the common drug aspirin, has mild analgesic,
antipyretic, and anti-inflammatory effects at moderate doses. At higher doses, however,
salicylate temporarily induces moderate hearing loss and the perception of a high-pitch
ringing in humans and animals. This phantom perception of sound known as tinnitus
is qualitatively similar to the persistent subjective tinnitus induced by high-level noise
exposure, ototoxic drugs, or aging, which affects ∼14% of the general population. For over
a quarter century, auditory scientists have used the salicylate toxicity model to investigate
candidate biochemical and neurophysiological mechanisms underlying phantom sound
perception. In this review, we summarize some of the intriguing biochemical and
physiological effects associated with salicylate-induced tinnitus, some of which occur in
the periphery and others in the central nervous system. The relevance and general utility
of the salicylate toxicity model in understanding phantom sound perception in general are
discussed.
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INTRODUCTION
Subjective tinnitus is characterized by the perception of a sound
in the absence of an acoustic source in the environment. A recent
health census in the United States indicated approximately 50
million adults report having experienced tinnitus and 16 million
experience it frequently (Shargorodsky et al., 2010).
Although the cochlea is responsible for transducing acoustic
signals into neural activity, it is becoming clear that the brain is
capable of generating neural activity of its own within the audi-
tory pathway leading to tinnitus perception. Subjective tinnitus
is primarily associated with sensorineural hearing loss (Norena
et al., 2002; Weisz et al., 2006) which may be the consequence
of loud noises, ototoxic drugs, or aging. While noise exposure is
likely the most common trigger of tinnitus (Axelsson and Sandh,
1985), several ototoxic drugs are known to cause tinnitus in
humans and animals. Among these are the chemotherapeutics
such as cisplatin (Bokemeyer et al., 1998; Rachel et al., 2002),
the antimalarial drug quinine (Kenmochi and Eggermont, 1997;
Ochi and Eggermont, 1997; Eggermont and Kenmochi, 1998;
Lobarinas et al., 2006; Ralli et al., 2010), and salicylate, the active
component of the non-steroidal anti-inflammatory drug aspirin
(Cazals, 2000). At therapeutic doses salicylate has mild analgesic,
anti-inflammatory, and antipyretic effects and is commonly used
for minor headaches and traditionally for rheumatic arthritis.
At high doses, however, salicylate causes temporary hearing loss
and reversible tinnitus, while hyperventilation, vertigo, confu-
sion, hemorrhaging, or death may result from extremely high
doses (Graham and Parker, 1948; Rauschka et al., 2007).
Since the establishment of a behavioral model of salicylate-
induced tinnitus in rats (Jastreboff et al., 1988a,b), the drug has
been used in various animal species to investigate the biologi-
cal mechanisms of tinnitus generation. Although the mechanisms
of tinnitus induction by salicylate may differ from those caused
by other hearing disorders, salicylate-induced tinnitus has several
distinct advantages over other methods of tinnitus induction such
as acute noise trauma. Two such advantages are the rapid induc-
tion and reversibility of salicylate-induced tinnitus. Following
oral consumption or systemic injection of the drug, tinnitus
presents within minutes and subsides within 72 h of the final dose
(Mongan et al., 1973). Interestingly, in a study by Mongan et al.
(1973), it was found that the majority of humans with preexist-
ing hearing loss (∼68%) did not report tinnitus despite very high
blood serum levels of salicylate. In rats, induction of tinnitus by
systemic administration of salicylate was found to be highly reli-
able with proper dosing (Lobarinas et al., 2006), whereas noise
trauma has a much more variable success of tinnitus induction
(Kraus et al., 2010).
Salicylate has several well-established effects on cochlear func-
tion; however, more recent experiments have highlighted the
drug’s direct modulation of neural activity in the brain. The
cochlear and central effects of salicylate should come as no
surprise since the drug rapidly enters cochlear perilymph and
cerebrospinal fluid simultaneously (Jastreboff et al., 1986). The
widespread distribution of the drug adds to the complexity of
understanding the mechanisms that are directly responsible for
salicylate-induced tinnitus. Here we review some critical features
of the salicylate toxicity model of tinnitus. We begin with a dis-
cussion of salicylate’s primary effects in the cochlea, followed
by its modulation of neurotransmitter systems and neural activ-
ity within the brain. Insights gained from the salicylate model
of tinnitus continue to inform researchers about the potential
mechanisms that lead to tinnitus perception.
COCHLEAR EFFECTS
Salicylate ototoxicity differs from most ototoxic drugs in that
hearing loss and tinnitus normally subside within 1–3 days
following cessation of treatment (Myers and Bernstein, 1965).
Several independent effects of salicylate on the peripheral
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auditory system have been identified, each of which likely con-
tribute to some aspect of the resulting hearing loss (summarized
in Figure 1). Furthermore, salicylate-induced tinnitus has been
hypothesized by some groups to be generated by altered cochlear
activity and transmitted with fidelity to the central auditory
system.
There exists a strong linear correlation between plasma levels
of unbound salicylate and the extent of decreased auditory sen-
sitivity (Day et al., 1989) reaching asymptote at a threshold of
∼40 dB elevation despite increased dosing (Myers and Bernstein,
1965; McFadden and Plattsmier, 1984); however, the relation-
ship of blood plasma salicylate levels to the presence of tinnitus
is much less predictable (Mongan et al., 1973; Halla et al., 1991).
This threshold shift can be accounted for by dysfunction of the
outer hair cell (OHC) active response to sound. Otoacoustic emis-
sions (OAEs) are acoustic signals generated by the electromotile
OHCs and serve to improve sensitivity and sharpen frequency
selectivity. Sound evoked OAEs, especially distortion product
OAEs (DPOAE), are reduced in humans and animals at low to
moderate stimulus levels during salicylate toxicity (Wier et al.,
1988; Kujawa et al., 1992; Fitzgerald et al., 1993; Guitton et al.,
2003; Ruel et al., 2008; Ralli et al., 2010; Stolzberg et al., 2011).
In vitro, salicylate alters membrane conductance and the shape
of OHCs (Douek et al., 1983; Shehata et al., 1991). Subsequent
experiments showed that salicylate acts as a competitive antago-
nist for the chloride anion binding site of prestin (Oliver et al.,
2001), the motor protein of OHCs, resulting in inhibition of
OHC motility (Kakehata and Santos-Sacchi, 1996; Zheng et al.,
2000).
Recently, we reported that acute systemic salicylate treatment
in ketamine/xylazine anesthetized rats (300mg/kg sodium sal-
icylate, i.p.) suppresses high and low frequency DPOAEs to a
greater extent than at middle frequencies (Stolzberg et al., 2011).
Interestingly, the region of greatest sensitivity following salicylate
corresponded to the behaviorally estimated pitch of tinnitus in
rats (Yang et al., 2007; Kizawa et al., 2010).
The active generation of a sound within the cochlea by spon-
taneous OAEs (SOAEs) was an early hypothesis pointing to a
peripheral generator of tinnitus (Wilson, 1980). SOAEs can be
measured in∼38% of the population (Wier et al., 1984); however,
most people with SOAEs do not have tinnitus. Conversely, SOAEs
are absent in many people with tinnitus (Zurek, 1981). Salicylate
treatment reduces or abolishes SOAEs in humans (McFadden and
Plattsmier, 1984; Wier et al., 1988). Thus, SOAEs are unlikely to
be a generator of the tinnitus signal.
Other measures of cochlear function, such as the cochlear
microphonic (CM) and summating potential (SP), have been
evaluated following local or systemic salicylate administration.
The CM is an electrical signal that reflects the net flow of ionic
currents alternating across cellular membranes in response to
a periodic sound stimulus such as a tone. The CM, therefore,
provides a gross index of the permeability of primarily OHCs
of the inner ear. The CM has been shown to be unaffected in
guinea pigs following cochlear perfusion of salicylate in response
to 10 kHz tones (Puel et al., 1990), but increased in response
to 1 kHz tones (Fitzgerald et al., 1993). Fitzgerald et al. (1993)
attributed the different results of the two studies to the choice
FIGURE 1 | Effects of systemic or cochlear perfusion of salicylate on
spontaneous (Spont.) or sound-evoked (Evoked) cochlear measures.
OAE, otoacoustic emissions; SP, summating potential; CM, cochlear
microphonic; CAP, compound action potential. 1. Fitzgerald et al. (1993); 2.
Puel et al. (1990); 3. Stolzberg et al. (2011); 4. Ruel et al. (2008); 5. Ralli et al.
(2010); 6. Guitton et al. (2003); 7. Wier et al. (1988); 8. Janssen et al. (2000);
9. McFadden and Plattsmier (1984); 10. Muller et al. (2003); 11. Didier et al.
(1993); 12. Silverstein et al. (1967); 13. Guitton et al. (2005); 14. Chen et al.
(2010); 15. Cazals et al. (1998) (∗spontaneous cochleoneural activity was
decreased immediately after injection and increased on longer timescale;
see text).
of stimulus frequency. The SP is a measure of the direct-current
response of hair cells to sound recorded from the round window
of the cochlea and most likely reflects both IHC and OHC func-
tion (Durrant et al., 1998). Cochlear perfusion of salicylate did
not have an effect on SP in guinea pigs (Puel et al., 1990).
Auditory nerve (AN) fiber recordings following systemic sal-
icylate administration have yielded variable results, most likely
attributable to differential effects of moderate versus high dosing
levels. In cats, Evans and Borerwe (1982) observed a significant
increase in spontaneous firing rates following a high dose of
sodium salicylate (400mg/kg i.v.) in a subpopulation of AN fibers
with baseline high spontaneous rate. This dose is extremely high
for the cat since a slightly lower dose (350mg/kg i.p.) has been
reported to result in hyperventilation and death (Silverstein et al.,
1967). In contrast, AN fibers in gerbils showed a small, yet sig-
nificant, decrease in spontaneous firing rates in fibers with low
characteristic frequencies (CFs) and no change in fibers with high
CFs following a moderate dose of salicylate (200mg/kg i.p. sal-
icylic acid) (Muller et al., 2003). Kumagai (1992) reported that
a high systemic dose (400mg/kg i.v. sodium salicylate) signif-
icantly increased AN spontaneous firing rates in guinea pigs,
whereas spontaneous firing rates were not affected by the low
systemic dose (200mg/kg i.v. sodium salicylate). The lower dose
of salicylate, although it did not alter spontaneous activity in
Frontiers in Systems Neuroscience www.frontiersin.org April 2012 | Volume 6 | Article 28 | 2
Stolzberg et al. Salicylate toxicity model of tinnitus
guinea pig AN, is sufficient to induce tinnitus-like behavior in rats
(Lobarinas et al., 2006).
The effects of long-term salicylate treatment on spontaneous
AN activity have also been investigated for changes in the average
spectrum of electrophysiological cochleoneural activity (ASECA)
recorded from a round window of guinea pigs (Cazals et al.,
1998). The magnitude of the ASECA measure reflects sponta-
neous activity of the AN. ASECA decreased following the initial
treatment of salicylate, but increased from baseline levels after
approximately 1 week of treatments (200mg/kg sodium salicylate,
i.m., twice per diem). The results from this study indicate that
acute dosing reduces spontaneous AN activity, whereas long-term
dosing increases spontaneous AN activity.
Recently, research has explored the mechanisms of increased
spontaneous AN fiber activity at very high doses of salicylate.
Salicylate confers many of its therapeutic effects through inhibi-
tion of the inducible form of cyclooxygenase, COX-2, an impor-
tant enzyme in the anti-inflammatory response of cells (Vane,
1998). The intracellular fatty acid, arachidonic acid, is a sec-
ond messenger that is cleaved by the COX-2 enzyme, resulting
in the synthesis of prostaglandins. The presence of arachidonic
acid in high concentrations is known to potentiate N-Methyl-
D-aspartate (NMDA) ionic currents in spiral ganglion neurons
(Miller et al., 1992). Peng et al. (2003) showed salicylate does
indeed potentiate NMDAcurrents in isolated pre-hearing postna-
tal mouse spiral ganglion cells. Ruel et al. (2008) further demon-
strated that salicylate potentiated NMDA currents in AN afferent
terminals by increasing available arachidonic acid. In addition,
perilymphatic perfusion of a high concentration of salicylate
(5mM) increased AN spontaneous firing rates (Ruel et al., 2008).
The same group (Guitton et al., 2005) demonstrated that block-
ade of NMDA channels prevented rats from developing salicylate-
induced tinnitus, supporting their hypothesis that tinnitus is
generated within the cochlea. In the study by Ruel et al. (2008),
increased spontaneous firing rates of AN fibers was proposed to
underlie tinnitus generation; however, the NMDA currents driv-
ing increased AN firing rates may only occur at extremely high
concentrations of salicylate, far above those sufficient to induce
tinnitus. In fact, the 5mM sodium salicylate used in this study
was the peak concentration measured in guinea pig perilymph
following systemic treatment with 460mg/kg (Jastreboff et al.,
1986), a dose well above that sufficient to induce behavioral evi-
dence of tinnitus in animals (Lobarinas et al., 2006). Indeed, Ruel
et al. (2008) indicated in their report that 1mM sodium salicy-
late failed to elicit detectable NMDA currents in spiral ganglion
neurons. Thus, some of the reported effects of salicylate in the
cochlea likely occur only at very high concentrations and may not
be directly involved in tinnitus generation per se, but may play a
role in determining the quality of the tinnitus percept. Anecdotal
evidence suggests that at extremely high dose levels of aspirin
alters the perception of tinnitus from reasonably tonal to cricket-
like (see discussion in McFadden et al., 1984). It is plausible that
a cricket-like perception may result from increased spontaneous
AN activity.
Overall, salicylate’s effects in the cochlea following systemic
administration manifest as a reduction of sound-driven activ-
ity, primarily due to the reduction of OHC electromotility.
Furthermore, at doses sufficient to induce tinnitus in animals, sal-
icylate does not seem to significantly increase spontaneous AN
activity. Taken together, the evidence from the literature seems
to argue against AN hyperactivity as the direct cause of tinni-
tus; therefore, the cochlea is not likely generating the tinnitus
signal. Moreover, a purely cochlear model of tinnitus generation
is problematic because spontaneous activity is always present in
the AN (Walsh et al., 1972) but does not normally cause tinnitus
perception. While spontaneous AN activity is important for the
encoding of acoustic signals (Koerber et al., 1966; Liberman and
Kiang, 1978), the brain is normally capable of tuning out periph-
eral spontaneous activity unrelated to acoustic stimulation; i.e.,
most people do not experience tinnitus despite having sponta-
neous AN activity. Based on anatomical and electrophysiological
studies of the brain in animal models of tinnitus, the following
sections provide compelling evidence for a central contribution
to salicylate-induced phantom sound perception.
CENTRAL EFFECTS
Salicylate clearly decreases the sensitivity of the sensory epithe-
lium to sound and may modulate the rate of spontaneous AN
transmission; however, there is also strong evidence that the drug
directly modulates neurotransmission in the brain. An early study
in human subjects provided evidence that the perception of tinni-
tus most often precedes self-reported hearing loss (Mongan et al.,
1973). Since salicylate is delivered to both the perilymph and
cerebrospinal fluid (Jastreboff et al., 1986), the report that tin-
nitus perception precedes self-reported hearing loss may indicate
that the brain is more sensitive to the presence of salicylate than
the cochlea. Furthermore, as discussed below, salicylate has been
found to directly modulate inhibitory neurotransmission in the
brain which may facilitate the rapidity at which phantom sound
is experienced following systemic administration of the drug. The
decreased cochlear sensitivity and/or alterations in spontaneous
firing rates in the AN may serve more to determine the tinnitus
pitch, whereas salicylate’s direct effects on the brain act to generate
and/or permit spurious neural activity to reach awareness.
IDENTIFYING KEY BRAIN REGIONS
Cytological markers of neural activity have been observed in
several auditory and non-auditory brain regions in salicylate-
induced tinnitus (Figure 2). The earliest studies used radioac-
tive glucose, [14C]2-deoxyglucose (2-DG) (Kauer et al., 1982;
Wallhausser-Franke et al., 1996); whereas more recent studies
have utilized immunolabeling of the immediate early gene c-fos
(Wallhausser-Franke, 1997; Wallhausser-Franke et al., 2003; Wu
et al., 2003), which is up-regulated in response to increased neu-
ral activity. Chronic systemic salicylate treatment at a dose known
to induce behavioral evidence of tinnitus in gerbils resulted in
reduced 2-DG uptake in the inferior colliculus (IC), particu-
larly in the high-frequency responsive region, while increased
uptake was observed in the auditory cortex (AC), as compared to
saline controls (Wallhausser-Franke et al., 1996). In subsequent
studies, small increases in c-fos were observed following acute
systemic salicylate treatment (350mg/kg i.p., sufficient to induce
tinnitus) in the dorsal cochlear nucleus (dCN) and the dorsal divi-
sion of the medial geniculate body (dMGB), but not in ventral
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FIGURE 2 | Summary of effects of salicylate on various auditory
structures. Cytological studies include results from 2-DG and fos-IR imaging
studies (see Section “Identifying Key Brain Regions”) and were performed at
low (50mg/kg i.p.) or high (350mg/kg i.p.) acute doses of salicylate.
Electrophysiology recordings were performed at various moderate to high
salicylate doses. Results are from studies using in vivo extracellular
recordings or in vitro extracellular or patch clamp recordings (see Section
“Electrophysiology”). AN, auditory nerve; vCN, ventral cochlear nucleus;
dCN, dorsal cochlear nucleus; cIC, central nucleus of the inferior colliculus;
eIC, external nucleus of the inferior colliculus; dIC, dorsal nucleus of the
inferior colliculus; vMGB, ventral portion of the medial geniculate body;
dMGB, dorsal portion of the medial geniculate body; A1, primary auditory
cortex; A2, secondary auditory cortex; AAF, anterior auditory field. Spont,
single unit or multiunit spontaneous firing rates; Evoked, sound-evoked single
unit or multiunit firing rates; ERP, sound-evoked response field potential;
CAP, compound action potential of the cochlea; IC, inferior colliculus response
potential; MGB, medial geniculate response potential; AC, auditory cortex
response potential. ∗Represents acute effects of salicylate treatment
(Wallhausser-Franke, 1997; Wallhausser-Franke et al., 2003). 2. Puel et al.
(1990); 3. Stolzberg et al. (2011); 6. Guitton et al. (2003); 7. Wier et al. (1988);
8. Janssen et al. (2000); 9. McFadden and Plattsmier (1984); 10. Muller et al.
(2003); 11. Didier et al. (1993); 12. Silverstein et al. (1967); 13. Guitton et al.
(2005); 14. Chen et al. (2010); 15. Cazals et al. (1998); 16. Evans and Borerwe
(1982); 17. Kumagai (1992); 18. Wei et al. (2010); 19. Basta et al. (2008); 20.
Sun et al. (2009); 21. Ma et al. (2006); 22. Basta and Ernst (2004); 23.
Jastreboff and Sasaki (1986); 24. Chen and Jastreboff (1995); 25. Lobarinas
et al. (2006); 26. Norena et al. (2010); 27. Lu et al. (2011); 28. Lobarinas et al.
(2006); 29. Paul et al. (2009); 30. Yang et al. (2007); 31. Eggermont and
Kenmochi (1998); 32. Kenmochi and Eggermont (1997); 33. Zhang et al.
(2011).
CN (vCN) or ventral MGB (vMGB) (Wallhausser-Franke, 1997;
Wallhausser-Franke et al., 2003). The largest increases in c-fos
expressing cells following salicylate (eight times the number of
cells than control) were observed in AC, especially in primary AC
(A1) and anterior auditory field (AAF) (Wallhausser-Franke et al.,
2003). In contrast, the central nucleus of the IC (cIC) was virtu-
ally free of c-fos and only a moderate increase was observed in
dorsomedial IC (dIC) (Wallhausser-Franke, 1997), which receives
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descending fibers from AC and does not belong to the ascending
auditory pathway (Faye-Lund, 1985). Chronic dosing of salicylate
in rats showed similar results for the CN and dIC, but differed in
that increased c-fos was additionally observed in cIC (Wu et al.,
2003). Interestingly, four times the number of cells expressing
c-fos was observed in AC following systemic treatment of sali-
cylate at a low dose (50mg/kg), which is insufficient to induce
behavioral evidence of tinnitus (Wallhausser-Franke et al., 2003).
In the same study, a faint increase in c-fos expression was also
observed in IC following the low, but not the high dose of sali-
cylate. These results indicate that salicylate has effects on neural
activity in the brain even at sub-tinnitus-inducing doses, indicat-
ing that the brain, and in particular AC, is highly sensitive to the
presence of salicylate.
Paul and colleagues (2009) used ametabolic tracer, fluorine-18
deoxyglucose (FDG), and positron imaging tomography (PET) to
image activity in the entire rat brain following a single dose of
sodium salicylate (250mg/kg i.p.). Metabolic activity was signif-
icantly increased in IC and AC; a small trend toward an increase
was measured in the thalamus, but this did not reach statisti-
cal significance. The greatest increase in metabolic demands was
observed in AC, followed by the IC, corroborating the results
from immunocytochemistry experiments described above.
Holt and colleagues investigated the effects of chronic salicylate
(3 consecutive days at 300mg/kg i.p) in rats using manganese-
enhanced MRI, a technique that assesses brain activity based on
the uptake of manganese into active neurons (Holt et al., 2010).
This technique, which has substantially higher spatial resolu-
tion than PET, measured significantly increased signal strength
in dCN, but not in vCN, following chronic salicylate treat-
ment, supporting the results of earlier c-fos studies. A significant
increase in signal strength in cIC, dIC, and external nucleus
of the IC (eIC) are consistent with earlier cytological stud-
ies after chronic salicylate dosing protocol (Wallhausser-Franke
et al., 1996; Wu et al., 2003). Interestingly, this MRI study did
not observe any significant changes in AC following salicylate
treatment, whereas previous 2-DG studies with a similar dosing
protocol had observed significant c-fos and metabolic activity in
AC (Wallhausser-Franke et al., 1996; Paul et al., 2009).
Wallhäuser-Franke concluded: “If tinnitus is evoked by the
effects of salicylate on the cochlea, increased c-fos immunoreac-
tivity would be expected in auditory brainstem nuclei, especially
since auditory stimulation readily evokes c-fos expression, for
example in IC (see discussion in Wallhausser-Franke, 1997).”
Following acoustic stimulation, the lemniscal auditory pathway
structures (vCN, cIC, vMGB, and A1) all exhibit elevated c-fos
expression (Carretta et al., 1999). As discussed in the previ-
ous section (see Section “Cochlear Effects”), if acute salicylate
treatment does indeed increase spontaneous firing rates of AN
fibers (Evans and Borerwe, 1982; Ruel et al., 2008) then 2-DG
uptake and c-fos would be expected to be enhanced in the vCN,
cIC, and vMGB. The apparent lack of c-fos within the lem-
niscal auditory structures following acute dosing of salicylate
suggests that tinnitus-related hyperactivity originates within the
brain and is related primarily to the AC and extralemniscal mid-
brain and brainstem structures (dMGB, dIC, and dCN). Results
from immunocytochemistry studies are, therefore, more in line
with the observations of reduced AN spontaneous firing rates
recorded in gerbils followingmoderate systemic doses of salicylate
sufficient to induce tinnitus (Muller et al., 2003).
While cytological studies support the hypothesis that central
auditory structures play a critical role in tinnitus generation, it
remains unclear if the hyperactivity in these auditory structures
is the result of direct action of the drug on neural activity, the
indirect result of dynamic adjustments of neural networks to
decreased peripheral output, or a complex interaction between
these peripheral and central effects. Furthermore, it should be
noted that although this review is focused on alterations along the
classical auditory pathway following salicylate, effects have been
observed in other brain regions, such as limbic structures, and
may play important roles in tinnitus (Wallhausser-Franke, 1997).
In the following subsections, we will discuss evidence that sal-
icylate does indeed directly modulate neurotransmission in the
brain.
EFFECTS ON GABAergic NEUROTRANSMISSION
Salicylate has been shown to directly affect neurotransmitter sys-
tems in the brain. One important factor in salicylate-induced
tinnitus is the drug’s apparent direct actions on γ-aminobutyric
acid (GABA) inhibitory neurotransmission in the brain.
Chronic treatment with salicylate in rats resulted in the
increased expression of glutamic acid decarboxylase (GAD65),
the GABA synthesizing enzyme, in IC (Bauer et al., 2000). The
increase in GAD was postulated to be compensatory for increased
neural traffic. In the same study, a significant increase in GABAA
receptor affinity in cIC, eIC, and dIC was measured. These
changes may be the result of increased neural activity, direct
effects of salicylate on GAD activity, or both. Indeed, changes
in GAD concentration following salicylate treatment may be the
result of direct inhibition of GAD enzymatic activity by salicy-
late (Gould et al., 1963; Gould and Smith, 1965); however, these
effects were measured at relatively high concentrations in vitro.
Functional changes of GABAergic interneurons in the auditory
system have also been observed. Salicylate applied to brain slices
(1.4mM) significantly decreased the frequency and amplitude
of current-evoked and spontaneous-miniature inhibitory post-
synaptic currents of AC layer 2/3 pyramidal cells (Wang et al.,
2006). Furthermore, the same group later showed that salicy-
late selectively and reversibly silences current-evoked activity of
fast-spiking inhibitory interneurons, but not of regular spiking
inhibitory or excitatory pyramidal neurons within AC (Su et al.,
2009). Such a decrease in GABAergic inhibition in AC by the
direct action of salicylate has been proposed to permit hyperac-
tivity within this region following acute treatment of salicylate
observed in earlier cytological studies (see Section “Auditory
Cortex”).
Effects of salicylate onGABAergic neurotransmission have also
been observed outside of the classic central auditory pathway.
Similar to the results in A1 described above, both evoked and
spontaneous inhibitory postsynaptic currents were decreased in
excitatory neurons in the CA1 region of the hippocampus (Gong
et al., 2008). Similar observations were made in the dorsal horn
of rat spinal dorsal horn neurons (Xu et al., 2005). These results
indicate that, at least in vitro, salicylate, at the concentrations
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used (generally 1.4mM), exerts its greatest effects on highly active
inhibitory neurons.
Taken together, both in vitro and in vivo experiments indicate
that acute dosing of salicylate generally depresses GABAergic neu-
rotransmission in the brain, whereas compensatory mechanisms,
such as increased GAD expression, are initiated following chronic
dosing protocols. Suchmodulation of GABAergic neurotransmis-
sion would be expected to significantly alter spontaneous and
stimulus-driven neural activity. However, as discussed next, the
results from some electrophysiology experiments corroborate the
salicylate-induced disinhibition hypothesis, whereas other exper-
iments indicate that salicylate has more complex modulation on
neurotransmission in the brain.
ELECTROPHYSIOLOGY
The consequences of salicylate treatment on sound-evoked and
spontaneous firing rates have been measured in many regions of
the mammalian auditory brain in vivo and/or in vitro (summa-
rized in Figure 2). In this section, we will review results from elec-
trophysiology studies of salicylate’s effects on brain regions along
the auditory pathway and compare them to results from noise-
exposures designed to induce tinnitus. Finding brain regions
which exhibit similar alterations in neural activity following sali-
cylate treatment or noise trauma will likely yield a framework for
understanding phantom sound perception in general.
Cochlear nucleus
As detailed above (see Section “Identifying Key Brain Regions”),
following acute systemic salicylate treatment, c-fos expression was
increased in dCN, but not in vCN. This result can be taken as
evidence that acute salicylate treatment primarily affects non-
lemniscal auditory structures. Indeed, activity in vCN tends to
follow AN activity, whereas activity in dCN is more heavily mod-
ulated by non-auditory brain regions (Koerber et al., 1966). To
the best of our knowledge electrophysiological recordings in dCN
following salicylate treatment have only been carried out in brain
slice preparations. Salicylate was found to either increase (52.9%)
or decrease (47.1%) spontaneous firing rates of a subpopulation
(68%) of neurons in dCN (Basta et al., 2008). In a more recent
patch clamp study, spontaneous and current-evoked firing rates
of fusiform cells, but not cartwheel cells, in the dCN were selec-
tively suppressed by salicylate (Wei et al., 2010). Furthermore,
inhibitory postsynaptic currents recorded in fusiform cells of the
dCN were significantly decreased by salicylate. These results indi-
cated that suppressed firing rates in fusiform cells were most likely
due to salicylate’s direct effects on the intrinsic properties of this
cell type and not the result of increased inhibition (Wei et al.,
2010).
Significantly elevated spontaneous firing rates have been
recorded from dCN fusiform cells in hamsters (Kaltenbach
et al., 2004) and chinchillas (Brozoski et al., 2002) with behav-
ioral evidence of tinnitus following exposure to loud tones. In
subsequent studies by Brozoski and colleagues it was demon-
strated that bilateral ablation of dCN in chinchillas with chronic
tinnitus did not abolish tinnitus behavior in affected animals
(Brozoski and Bauer, 2005); whereas ablation of dCN prior
to noise trauma prevented the induction of tinnitus (Brozoski
et al., 2012). While the dCN may play a role in the initial
generation of tinnitus symptoms following intense sound expo-
sure (Brozoski et al., 2012), the structure does not seem to be
required to maintain the tinnitus percept (Brozoski and Bauer,
2005).
Inferior colliculus
Some of the earliest evidence that salicylate has direct effects on
neural activity within the auditory brain was provided by elec-
trophysiological recordings of altered neural activity in the IC
following systemic delivery of salicylate. Following acute dos-
ing in guinea pigs anesthetized with pentobarbital, spontaneous
firing rates of a population of neurons in the eIC significantly
increased (Jastreboff and Sasaki, 1986; Chen and Jastreboff, 1995),
while the occurrence and duration of bursting type discharges
in eIC increased for neurons sensitive to sound frequencies near
the behaviorally assessed tinnitus pitch (Chen and Jastreboff,
1995). A mouse brain slice study observed similar frequency
specific increases in spontaneous firing rates in cIC and eIC
of neurons residing in anatomical regions receptive to sound
frequencies at the animal’s best hearing threshold (Basta and
Ernst, 2004). Recordings from cIC of ketamine/xylazine anes-
thetized mice showed that acute salicylate treatment significantly
decreased the occurrence of spontaneous bursting-type activity
from single units as well as decreased the coefficient of varia-
tion for interspike intervals, indicating more regular spontaneous
firing patterns (Ma et al., 2006). Furthermore, these changes
were found to be greatest for single units with best frequencies
below 27 kHz. Taken together, these electrophysiological results
seem to corroborate observations of increased c-fos in eIC while
the decreased spontaneous firing rates recorded in vivo agrees
with the small decrease of c-fos observed in cIC following acute
systemic treatment (Wallhausser-Franke, 1997).
Intravenous injection of lidocaine, a sodium channel blocker
used to temporarily alleviate tinnitus in humans with chronic tin-
nitus (Perucca and Jackson, 1985; Reyes et al., 2002), reduced the
salicylate-enhanced spontaneous firing rates of some guinea pig
IC neurons for more than 30 minutes (Manabe et al., 1997). It
is unclear from this study where in the IC these recordings were
performed. We can speculate that since previous studies observed
decreased spiking in cIC (Ma et al., 2006) and increased spiking
in eIC (Chen and Jastreboff, 1995) that lidocaine may have been
acting on neurons in eIC.
The amplitude of sound-evoked local field potentials (LFPs)
recorded from the rat IC was unchanged following acute systemic
salicylate injection; however, since the sound-evoked cochlear
response (CAP) is decreased by salicylate treatment (see Section
“Cochlear Effects”), the stable sound-evoked LFP amplitude of
the IC indicates the neural signal was enhanced to a small degree
in the brainstem (Sun et al., 2009). In the same study, appli-
cation of sodium salicylate to the round window resulted in
both decreased CAP amplitude and a correspondingly reduced
sound-evoked LFP recorded from IC. These results provide fur-
ther evidence that salicylate acts on the cochlea as well as
directly on brain, most likely through the reduction of central
inhibitory neurotransmission (see Section “Effects on GABAergic
Neurotransmission”).
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Studies using the acute noise trauma model of tinnitus have
observed increased spontaneous firing rates in the cIC near the
exposure frequency after a week or more following noise expo-
sure (Ma et al., 2006; Mulders and Robertson, 2009). Mulders and
Robertson (2009) further demonstrated that inactivation, chem-
ically, by cooling, or by complete ablation of the noise-exposed
cochlea, reduced spontaneous firing rates of the contralateral cIC
neurons compared to those of control animals. These results indi-
cate that significantly enhanced spontaneous activity in cIC weeks
after noise exposure still requires afferent input to exhibit these
changes. While increased spontaneous activity weeks following
noise trauma differs from acute salicylate treatment, where a
decrease in c-fos was found in cIC (Wallhausser-Franke et al.,
2003), chronic salicylate treatment similarly increased c-fos and
2-DG uptake in cIC (Wallhausser-Franke et al., 1996; Wu et al.,
2003).
The role of the cIC in tinnitus may be different on short
and long time scales. In acutely induced tinnitus from either
noise trauma or salicylate, spontaneous firing rates in cIC do
not increase immediately (salicylate or noise in mouse, Ma et al.,
2006; noise in guinea pigs, Mulders and Robertson, 2009). In
the case of noise trauma, spontaneous rates in the dCN and cIC
increase starting 7 days or more after the exposure (Kaltenbach
et al., 2004; Mulders and Robertson, 2009). Taken together, these
results indicate that chronic, but not acute tinnitus may be
associated with increased spontaneous firing in cIC.
One common feature between salicylate- and noise-induced
tinnitus is the enhancement of the sound-evoked LFP recorded
from the IC (Salvi et al., 1990; Mulders and Robertson, 2009; Sun
et al., 2009). This enhanced response to sound may reflect a disin-
hibition in IC following manipulations that induce tinnitus. The
precise location of this enhancement within the IC, (i.e., within
cIC, dIC, or eIC), has yet to be determined.
Medial geniculate body
The only electrophysiological recordings of salicylate’s effects on
neural activity inMGB have been from extracellular recordings in
vitro (Basta et al., 2008). In this study, the MGB (dorsal and ven-
tral cells were analyzed together) exhibited the greatest propor-
tion of neurons which had significantly altered spontaneous firing
rates during salicylate application (dCN: 68.0%; MGB: 80.8%;
AC: 71.4% of all recorded neurons); however, the direction of
change in spontaneous firing rates of this MGB cell population
were roughly equivalent (52.4% increase, 47.6% decrease).
We are unaware of any existing studies directly investigating
the role of MGB in noise-induced tinnitus. Since MGB and the
reticular nucleus of the thalamus play a critical role in gating audi-
tory neural activity, these regions in concert with AC have been
proposed to play a critical role in tinnitus perception (Llinas et al.,
1999).
Auditory cortex
The effects of salicylate on spontaneous and sound-evoked neural
activity within the auditory pathway have been most extensively
studied in AC. The attention paid to this specific brain region may
be warranted since several studies in animals have measured the
largest changes in AC following acute systemic salicylate adminis-
tration. Cytological studies indicate that metabolic activity in the
core auditory cortex (A1 and AAF) was increased to the great-
est extent over other auditory brain regions (Wallhausser-Franke
et al., 2003, and see Section “Identifying Key Brain Regions”).
The increased metabolic activity is presumed to reflect increased
spontaneous neural activity; however, electrophysiology studies
of AC do not seem to be in full agreement with this interpre-
tation. In A1 and AAF, a small decrease in spontaneous firing
rates has been measured following salicylate (Eggermont and
Kenmochi, 1998; Yang et al., 2007; Lu et al., 2011), whereas a
significant increase in secondary auditory cortex (A2) sponta-
neous firing rates was observed in anesthetized cats (Eggermont
and Kenmochi, 1998). Since A1 and AAF receive projections pri-
marily from the ascending lemniscal auditory pathway by way
of vMGB (Huang and Winer, 2000), a small decrease observed
in these regions may simply reflect the decreased cochlear out-
put following salicylate treatment. In contrast, A2 is more heavily
innervated by extralemniscal projections originating in dMGB
(Huang and Winer, 2000). The increase in spontaneous neural
activity in A2 may therefore indicate that the extralemniscal audi-
tory structures play a more central role in salicylate-induced tin-
nitus. Furthermore, Eggermont and Kenmochi (1998) suggested
that the presence of an incongruity in spontaneous firing rates
across fields of AC may be an important feature distinguishing
tinnitus-driven from acoustically driven sound perception.
The involvement of spontaneous activity in A1 during tinni-
tus induced by noise trauma has not been heavily investigated.
Engineer et al. (2011) recorded sound-driven and spontaneous
neural activity in A1 of rats 1 month following acute noise
trauma. Rats with signs of tinnitus following noise exposure,
assessed using the gap pre-pulse inhibition of the acoustic star-
tle reflex paradigm, exhibited significantly increased spontaneous
firing rates in A1; however, the reversal of signs of tinnitus using
vagal-nerve stimulation paired with tones resulted in an addi-
tional increase in spontaneous firing rates. The authors conclude
that increased spontaneous firing rates of neurons in A1 were not
significantly correlated with evidence of tinnitus in rats.
In addition to simple spontaneous firing rates, other interest-
ing changes in neural activity in AC have been observed follow-
ing salicylate treatment. Ochi and Eggermont (1996) described
changes in the temporal dynamics of spontaneous neural activity
in A1 associated with salicylate treatment that may be more infor-
mative than simple statistics of population spontaneous firing
rates. Salicylate was found to significantly increase the rebound
to peak of the autocorrelation function, a mathematical tool used
to look for repeating firing patterns of an individual neuron,
indicating each spontaneous spike was followed by a prolonged
interval before the next spike occurred. Furthermore, neurons
in A1 were best modulated by click trains at slower presenta-
tion rates following salicylate. These changes in the temporal
dynamics of A1 neural activity were hypothesized to be caused by
increased afterhyperpolarization (AHP) resulting from enhanced
activation of slow conducting Ca2+-activated K+-channels of cor-
tical neurons (Ochi and Eggermont, 1996). The rationale for this
hypothesis stems from studies of salicylate’s action on periph-
eral nerve membranes at relatively high concentrations (20mM,
Neto et al., 1980) compared to those levels measured in cere-
brospinal fluid following systemic treatment (1.4mM, Jastreboff
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et al., 1986). In a more recent brain slice patch clamp study, a
lower concentration of salicylate (1.4mM) failed to significantly
alter AHP amplitude in AC neurons (Su et al., 2009). Additional
in vivo studies with pharmacological manipulations are required
to better understand the basis for the altered temporal dynamics
observed in A1.
Sound-evoked activity in AC is greatly altered by systemi-
cally administered or locally applied salicylate (Lobarinas et al.,
2006; Sun et al., 2009; Norena et al., 2010; Lu et al., 2011).
Since the sound-evoked CAP is decreased in the cochlea by either
route of delivery, the enhanced AC response indicates a signal
gain increase occurs within the brain (Sun et al., 2009). Sun
et al. (2009) recorded sound-evoked LFPs from electrodes chron-
ically implanted over AC in awake and anesthetized rats before
and after salicylate treatment. In awake rats, the amplitude of
sound-evoked AC response was significantly enhanced following
systemic dose of salicylate (200mg/kg i.p). Responses in AC were
further enhanced in the same rats while under ketamine (NMDA
receptor antagonist) anesthesia, whereas they were suppressed
while under isoflurane (GABAA receptor agonist) anesthesia.
In a subsequent study, application of salicylate (2mM) to the
brain surface over AC had similar effects on spontaneous (small
decrease) and sound-evoked multiunit firing rates (significant
increase) providing further evidence that these changes can be
attributed to the direct effects of salicylate on the brain (Lu et al.,
2011). Furthermore, co-application of the GABA transaminase
inhibitor vigabatrin, which effectively increases the concentration
of available GABA, or the GABAB receptor agonist baclofen to
the brain surface reduced the salicylate-induced enhancement of
sound-evoked multiunit firing rates (Lu et al., 2011).
Recently we showed that systemic salicylate treatment has sig-
nificant and rapid effects on frequency receptive field tuning
of neurons in the anesthetized rat A1 (Stolzberg et al., 2011).
Following systemic administration of salicylate (250 or 300mg/kg
i.p.) the characteristic frequency, i.e., the sound frequency at
which units weremost sensitive, tended to shift toward 10–20 kHz
(Figure 3), frequencies which coincide with the pitch of salicylate-
induced tinnitus determined from previous behavioral studies.
We hypothesized that this dramatic change in the frequency sen-
sitivity of neurons in A1 may be the result of two coincident
effects of salicylate. First, salicylate significantly altered the profile
of OHC sensitivity with the greatest reduction at low (<10 kHz)
and high (>20 kHz) sound frequencies (in rat, Stolzberg et al.,
2011). Additionally, salicylate had greater effects on high fre-
quencies resulting in a somewhat sloping high-frequency hearing
loss beginning at 16 kHz. Second, a decrease in cortical inhibi-
tion (Wang et al., 2006; Su et al., 2009; Lu et al., 2011) may
result in shifting of neuronal characteristic frequencies on a
rapid timescale. The overrepresentation of frequency along the
tonotopic gradient of A1 has been observed following acoustic
trauma (Irvine et al., 2000; Eggermont and Komiya, 2000), var-
ious learning paradigms using acoustic stimuli (Edeline et al.,
1993; Rutkowski and Weinberger, 2005), and in humans with
chronic tinnitus (Wienbruch et al., 2006). It has been proposed
that an overrepresentation of a frequency along the tonotopic gra-
dient in A1 may reflect the relative behavioral importance of a
sound to the organism (Rutkowski and Weinberger, 2005).
In humans, a magnetoencephalography study by Wienbruch
et al. (2006) observed a flattening of the tonotopic gradient and
an enhanced dipole response using 40-Hz auditory stimuli in A1
FIGURE 3 | Frequency tuning of eight simultaneously recorded
extracellularly recorded multunits from primary auditory cortex before
(top panel) and after systemic salicylate injection (bottom panel;
250mg/kg i.p.). Following systemic salicylate treatment, the frequency
tunings of tracked multiunits shifted maximal frequency sensitivities toward
the 10–20 kHz frequency region, near the estimated tinnitus pitch. Please see
Stolzberg et al., 2011 for population statistics. [From Stolzberg et al. (2011)
with permission].
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of tinnitus subjects compared with controls. Recently, Engineer
et al. (2011) demonstrated that the pairing of vagal nerve stim-
ulation with tones was able to retune the distorted tonotopic
gradient in A1 of rats with evidence of noise-induced tinnitus.
The retuning of A1 tonotopy using the vagal nerve stimulation
protocol reduced the number of rats with evidence of tinnitus
using the gap-prepulse inhibition of the acoustic startle reflex test.
The authors also found that distortion of the tonotopic gradient
and broadening of tuning curves in A1 was significantly corre-
lated with the degree of gap detection impairment (interpreted as
the presence of tinnitus); however, changes in spontaneous firing
rates or synchronization were not found to be correlated with the
presence of tinnitus (Engineer et al., 2011).
Tonotopic overrepresentation in A1 has been proposed to
result from the unmasking of normally inhibited intracortical
connections (Eggermont and Roberts, 2004). Furthermore, the
overrepresentation of frequencies in A1 results in an enhanced
sound-evoked field potential. It remains uncertain whether or
not such an overrepresentation is responsible for the generation
of tinnitus signal or if it reflects persistent spontaneous neural
activation somewhere else along the auditory pathway.
DISCUSSION
The salicylate toxicity model differs from the noise trauma model
of tinnitus in several respects; however, a few aspects shared by the
two models may facilitate the identification of key brain regions
and patterns of neural activity involved in tinnitus perception in
general.
PERIPHERAL OR CENTRAL?
One critical aspect to understanding the origins of tinnitus is
whether a persistent signal is generated in the ear or abnormal
patterns of neural activity occur within the brain. In humans
with persistent subjective tinnitus, neural activity closely linked
to changes in tinnitus loudness have been observed in AC, medial
geniculate and other sites within the central nervous system
(Lockwood et al., 1998; Muhlnickel et al., 1998; Lockwood et al.,
2001; Reyes et al., 2002). Since salicylate is delivered to the
brain and cochlea simultaneously following systemic treatment
(Jastreboff et al., 1986) it is difficult to make a clear dissocia-
tion between the drug’s peripheral and central effects. One of
the primary sources of confusion regarding the locus of salicy-
late’s generation of tinnitus signal, and the utility of the drug as a
model for more common manifestations of tinnitus (i.e., follow-
ing noise trauma or presbycusis), stems from the use of very high
concentrations of sodium salicylate in AN fiber recordings.
Systemic treatment with sodium salicylate at moderate doses
capable of inducing tinnitus either does not affect or slightly
decreases spontaneous firing rates of AN fibers (Kumagai, 1992;
Muller et al., 2003); however, at very high concentrations, salicy-
late begins to induce effects in the inner ear resulting in increased
AN spontaneous firing rates (Evans and Borerwe, 1982; Ruel
et al., 2008). Since behavioral evidence of tinnitus can be induced
at the moderate doses of salicylate (Myers and Bernstein, 1965;
Lobarinas et al., 2006), effects observed at very high concentra-
tions of the drug may be difficult to directly relate to tinnitus gen-
eration or perception. Evidence from cytological studies which
used acute salicylate treatment at moderate doses indicate that
brain regions associated with the ascending lemniscal auditory
system show either a decrease or no change in markers related
to neural activity (Wallhausser-Franke et al., 2003). Since acous-
tic stimulation activates the lemniscal auditory pathway (Carretta
et al., 1999), whereas acute systemic salicylate treatment at a
moderate dose does not (Wallhausser-Franke, 1997; Wallhausser-
Franke et al., 2003), it is unlikely that salicylate concentrations
sufficient to induce tinnitus increase AN spontaneous firing rates.
With regards to spontaneous AN activity, the use of a moderate
dose of salicylate seems to be in agreement with other manipu-
lations which induce decreased cochlear sensitivity, such as noise
trauma (Liberman and Kiang, 1978) or selective inner hair cell
loss (Wang et al., 1997). Taken together, it is likely that an acute
moderate dose of salicylate induces tinnitus by alteration of neu-
ral activity within the brain and not inherited from increased
spontaneous AN activity. Following salicylate, changes in cochlear
sensitivity may, however, play a role in determining the pitch of
tinnitus (Stolzberg et al., 2011).
TIME COURSE OF SALICYLATE’S ACTIONS
Existing research on the central effects of salicylate seems to be
approximately split equally between acute and chronic dosing
protocols. As discussed throughout this review, it is critical to
consider the time course of effects following systemic salicylate
treatment. Immediately following acute systemic treatment with
salicylate, the extralemniscal pathway rapidly becomes hyperac-
tive whereas spontaneous firing rates within lemniscal auditory
structures remain relatively stable. On the other hand, chronic
systemic salicylate treatment increases spontaneous firing rates
within the lemniscal pathway (Wallhausser-Franke et al., 1996;
Wu et al., 2003). These differential effects of acute and chronic
salicylate treatment regimens are important to keep in mind
while seeking putative mechanisms of salicylate-induced tinni-
tus. Studying the effects of acute and chronic salicylate treatment
may yield information about various aspects of the drug’s actions
in the cochlea and the brain. Since tinnitus occurs rapidly after
systemic administration of salicylate, the results from acute sal-
icylate treatment in animals are likely to be highly informative
about which brain regions are involved in the tinnitus percep-
tion per se, whereas the results from studying chronic salicylate
treatment may be more informative regarding compensatory bio-
chemical and neural mechanisms which may be targets for tuning
out the tinnitus. One example of a compensatory mechanism
is enhanced prestin expression and increased DPOAE response
following chronic salicylate treatment (Huang et al., 2005; Yang
et al., 2009; Chen et al., 2010).
UTILITY OF SALICYLATE TOXICITY AS A MODEL FOR TINNITUS
Induction of tinnitus using salicylate has a few important advan-
tages over other methods of induction such as noise trauma.
First, salicylate acts rapidly to induce tinnitus in subjects and is
metabolized within days in most species, providing the ability
to monitor physiological changes before, during, and after tinni-
tus. Second, the drug’s effects on GABAergic neurotransmission
may model other conditions which similarly decrease GABAergic
neurotransmission associated with tinnitus in humans such
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as aging (Caspary et al., 1995, 1999; Ling et al., 2005). Third,
salicylate can be administered to humans whereas intense noise
trauma is often unethical (however see Ortmann et al., 2011). A
fourth advantage is that the locus of drug delivery can be con-
trolled. This provides a means to dissociate the drug’s effects on
various brain regions in vitro and in vivo. Finally, with proper
dosing, salicylate can reliably induce tinnitus behavior in animals
(Jastreboff et al., 1988a,b; Lobarinas et al., 2006), whereas noise
trauma is highly variable at inducing tinnitus behavior in animals
(Kraus et al., 2010).
There are also some important inherent limitations of the
salicylate model of tinnitus. One such limitation of systemic
administration of salicylate is that the drug induces binaural hear-
ing loss and the perception of tinnitus is binaural. Unilateral
noise trauma provides the opportunity to study tinnitus-related
changes ipsilateral or contralateral to the exposed ear within indi-
vidual brains. The reliability of tinnitus induction by salicylate
may be considered a limitation of the model. The variable suc-
cess of noise trauma in inducing tinnitus permits experimenters
to identify potential mechanisms of susceptibility to tinnitus.
The utility of the salicylate toxicity model of tinnitus may ulti-
mately reside in which of the drug’s effects are similar with those
of noise induced tinnitus. On an acute time course, identifying
brain regions and abnormal patterns of neural activity coinci-
dent between multiple methods of tinnitus induction will likely
yield a greater understanding of tinnitus perception in general.
The entrenchment of the tinnitus signal in neural circuits on
the timescale of years (for example see Schlee et al., 2008), how-
ever, may not be an approachable aspect of subjective tinnitus to
investigate using the salicylate model.
REMAINING QUESTIONS
Some important experimental questions remain for tinnitus
researchers which may be best approached using the salicylate
toxicity model:
• Why does acute salicylate administration increase neural activ-
ity in extralemniscal, but not lemniscal auditory structures?
• Does pre-ablation of the dCN prevent salicylate-induced tinni-
tus (see Section “Cochlear Nucleus”).
• What determines the behaviorally identified pitch of salicylate-
induced tinnitus? Is it determined solely by salicylate’s effects
in the cochlea? Or is it determined by alterations of tonotopic
gradients within the auditory brain?
• What do the differential effects of acute and chronic dosing of
salicylate tell us about neuroplasticity and the entrenchment of
the tinnitus signal?
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